1	3	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	Urine	_	_	NN	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	vital	_	_	JJ	_	_	_	_	_
5	biofluid	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	mammals	_	_	NNS	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	could	_	_	MD	_	_	_	_	_
10	be	_	_	VB	_	_	_	_	_
11	easily	_	_	RB	_	_	_	_	_
12	collected	_	_	VBN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	noninvasive	_	_	JJ	_	_	_	_	_
16	manner	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	metabolites	_	_	NNS	_	_	_	_	_
5	components	_	_	NNS	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	concentrations	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	urine	_	_	NN	_	_	_	_	_
10	are	_	_	VBP	_	_	_	_	_
11	good	_	_	JJ	_	_	_	_	_
12	indicators	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	metabolic	_	_	JJ	_	_	_	_	_
15	fluctuations	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Comparison	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	metabolite	_	_	NN	_	_	_	_	_
4	profiles	_	_	NNS	_	_	_	_	_
5	between	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	treatment	_	_	NN	_	_	_	_	_
8	group	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	control	_	_	NN	_	_	_	_	_
12	group	_	_	NN	_	_	_	_	_
13	could	_	_	MD	_	_	_	_	_
14	obtain	_	_	VB	_	_	_	_	_
15	metabolic	_	_	JJ	_	_	_	_	_
16	changes	_	_	NNS	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	reveal	_	_	VB	_	_	_	_	_
19	adverse	_	_	JJ	_	_	_	_	_
20	effects	_	_	NNS	_	_	_	_	_
21	mechanism	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	stressor	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	1H-NMR	_	_	NNP	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	UPLC-MS/MS	_	_	NNP	_	_	_	_	_
8	based	_	_	VBD	_	_	_	_	_
9	metabolomics	_	_	NNS	_	_	_	_	_
10	were	_	_	VBD	_	_	_	_	_
11	employed	_	_	VBN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	investigate	_	_	VB	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	metabolic	_	_	JJ	_	_	_	_	_
16	perturbations	_	_	NNS	_	_	_	_	_
17	after	_	_	IN	_	_	_	_	_
18	rac	_	_	NN	_	_	_	_	_
19	-metalaxyl	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	metalaxyl-M	_	_	NN	_	_	_	_	_
22	exposure	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	showed	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	both	_	_	DT	_	_	_	_	_
6	rac	_	_	NN	_	_	_	_	_
7	-metalaxyl	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	metalaxyl-M	_	_	NN	_	_	_	_	_
10	induced	_	_	VBD	_	_	_	_	_
11	systematic	_	_	JJ	_	_	_	_	_
12	metabolic	_	_	JJ	_	_	_	_	_
13	changes	_	_	NNS	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	urine	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	serum	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Rac	_	_	NNP	_	_	_	_	_


1	-metalaxyl	_	_	NN	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	metalaxyl-M	_	_	NN	_	_	_	_	_
4	induced	_	_	VBN	_	_	_	_	_
5	liver	_	_	NN	_	_	_	_	_
6	damages	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	metabolic	_	_	JJ	_	_	_	_	_
9	pathway	_	_	NN	_	_	_	_	_
10	changes	_	_	NNS	_	_	_	_	_
11	including	_	_	VBG	_	_	_	_	_
12	glycine	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	serine	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	threonine	_	_	NN	_	_	_	_	_
18	metabolism	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	citrate	_	_	NN	_	_	_	_	_
21	cycle	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	TCA	_	_	NN	_	_	_	_	_
24	cycle	_	_	NN	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	pyruvate	_	_	NN	_	_	_	_	_
28	metabolism	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	glycolysis	_	_	NN	_	_	_	_	_
31	or	_	_	CC	_	_	_	_	_
32	gluconeogenesis	_	_	NN	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	glycerophospholipid	_	_	NN	_	_	_	_	_
35	metabolism	_	_	NN	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	glyoxylate	_	_	NN	_	_	_	_	_
39	and	_	_	CC	_	_	_	_	_
40	dicarboxylate	_	_	JJ	_	_	_	_	_
41	metabolism	_	_	NN	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	pathways	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	highly	_	_	RB	_	_	_	_	_
5	related	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	energy	_	_	NN	_	_	_	_	_
8	metabolism	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	lipid	_	_	NN	_	_	_	_	_
11	metabolism	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	amino	_	_	NN	_	_	_	_	_
14	acids	_	_	NNS	_	_	_	_	_
15	metabolism	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	microbial	_	_	JJ	_	_	_	_	_
18	metabolism	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	tryptophan	_	_	NN	_	_	_	_	_
22	metabolism	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	3.1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Body	_	_	NN	_	_	_	_	_
2	Weight	_	_	NN	_	_	_	_	_
3	Changes	_	_	NNS	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	Liver	_	_	NN	_	_	_	_	_
6	Damage	_	_	NN	_	_	_	_	_


1	Only	_	_	RB	_	_	_	_	_
2	one	_	_	CD	_	_	_	_	_
3	mouse	_	_	NN	_	_	_	_	_
4	was	_	_	VBD	_	_	_	_	_
5	dead	_	_	JJ	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	60	_	_	CD	_	_	_	_	_
9	mg/kg	_	_	NN	_	_	_	_	_
10	metalaxyl-M	_	_	NN	_	_	_	_	_
11	treatment	_	_	NN	_	_	_	_	_
12	group	_	_	NN	_	_	_	_	_
13	during	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	whole	_	_	JJ	_	_	_	_	_
16	experiment	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	After	_	_	IN	_	_	_	_	_
2	four	_	_	CD	_	_	_	_	_
3	weeks	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	exposure	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	no	_	_	DT	_	_	_	_	_
8	significant	_	_	JJ	_	_	_	_	_
9	changes	_	_	NNS	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	body	_	_	NN	_	_	_	_	_
12	weight	_	_	NN	_	_	_	_	_
13	were	_	_	VBD	_	_	_	_	_
14	observed	_	_	VBN	_	_	_	_	_
15	between	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	control	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	treatment	_	_	NN	_	_	_	_	_
20	groups	_	_	NNS	_	_	_	_	_
21	after	_	_	IN	_	_	_	_	_
22	rac	_	_	NN	_	_	_	_	_
23	-metalaxyl	_	_	NN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	metalaxyl-M	_	_	NN	_	_	_	_	_
26	exposure	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Histopathology	_	_	NN	_	_	_	_	_
2	examination	_	_	NN	_	_	_	_	_
3	showed	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	rac	_	_	NN	_	_	_	_	_
6	-metalaxyl	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	metalaxyl-M	_	_	NN	_	_	_	_	_
9	can	_	_	MD	_	_	_	_	_
10	both	_	_	DT	_	_	_	_	_
11	induce	_	_	VB	_	_	_	_	_
12	hepatocellular	_	_	JJ	_	_	_	_	_
13	inflammation	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	necrosis	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	vacuolation	_	_	NN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	mice	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Such	_	_	JJ	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	suggested	_	_	VBD	_	_	_	_	_
4	rac	_	_	NN	_	_	_	_	_
5	-metalaxyl	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	metalaxyl-M	_	_	NN	_	_	_	_	_
8	exposure	_	_	NN	_	_	_	_	_
9	caused	_	_	VBN	_	_	_	_	_
10	liver	_	_	NN	_	_	_	_	_
11	dysfunction	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	mice	_	_	NNS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	metalaxyl-M	_	_	NN	_	_	_	_	_
4	induced	_	_	VBD	_	_	_	_	_
5	greater	_	_	JJR	_	_	_	_	_
6	liver	_	_	NN	_	_	_	_	_
7	damage	_	_	NN	_	_	_	_	_
8	than	_	_	IN	_	_	_	_	_
9	rac	_	_	FW	_	_	_	_	_
10	-metalaxyl	_	_	NN	_	_	_	_	_
11	at	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	same	_	_	JJ	_	_	_	_	_
14	dosage	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	liver	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	fundamental	_	_	JJ	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	essential	_	_	JJ	_	_	_	_	_
8	organ	_	_	NN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	metabolism	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	detoxification	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	xenobiotics	_	_	NNS	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	abundant	_	_	JJ	_	_	_	_	_
17	cytochrome	_	_	NN	_	_	_	_	_
18	P450	_	_	NN	_	_	_	_	_
19	enzymes	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	damages	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	liver	_	_	NN	_	_	_	_	_
6	may	_	_	MD	_	_	_	_	_
7	greatly	_	_	RB	_	_	_	_	_
8	affect	_	_	VB	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	detoxification	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	mice	_	_	NNS	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	3.2	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Energy	_	_	NN	_	_	_	_	_
2	Metabolism	_	_	NN	_	_	_	_	_


1	Metabolites	_	_	NNS	_	_	_	_	_
2	involved	_	_	VBN	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	energy	_	_	NN	_	_	_	_	_
5	metabolism	_	_	NN	_	_	_	_	_
6	were	_	_	VBD	_	_	_	_	_
7	significant	_	_	JJ	_	_	_	_	_
8	changed	_	_	VBN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	mice	_	_	NNS	_	_	_	_	_
11	urine	_	_	NN	_	_	_	_	_
12	after	_	_	IN	_	_	_	_	_
13	rac	_	_	NN	_	_	_	_	_
14	-metalaxyl	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	metalaxyl-M	_	_	NN	_	_	_	_	_
17	exposure	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	including	_	_	VBG	_	_	_	_	_
20	citrate	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	succinate	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	lactate	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	alanine	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	pyruvate	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	acetate	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	metabolites	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	highly	_	_	RB	_	_	_	_	_
5	related	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	energy	_	_	NN	_	_	_	_	_
8	pathways	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	including	_	_	VBG	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	TCA	_	_	NN	_	_	_	_	_
13	cycle	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	pyruvate	_	_	NN	_	_	_	_	_
16	metabolism	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	glycolysis	_	_	NN	_	_	_	_	_
20	or	_	_	CC	_	_	_	_	_
21	gluconeogenesis	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Citrate	_	_	NNP	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	succinate	_	_	NN	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	main	_	_	JJ	_	_	_	_	_
7	intermediates	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	TCA	_	_	NNP	_	_	_	_	_
11	cycle	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	which	_	_	WDT	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	mainly	_	_	RB	_	_	_	_	_
16	appeared	_	_	VBN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	liver	_	_	NN	_	_	_	_	_
19	mitochondria	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	other	_	_	JJ	_	_	_	_	_
3	factors	_	_	NNS	_	_	_	_	_
4	cannot	_	_	MD	_	_	_	_	_
5	be	_	_	VB	_	_	_	_	_
6	excluded	_	_	VBN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	increased	_	_	VBN	_	_	_	_	_
10	levels	_	_	NNS	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	citrate	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	succinate	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	urine	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	metalaxyl-M-treated	_	_	JJ	_	_	_	_	_
20	mice	_	_	NNS	_	_	_	_	_
21	indicated	_	_	VBD	_	_	_	_	_
22	that	_	_	IN	_	_	_	_	_
23	metalaxyl-M	_	_	NN	_	_	_	_	_
24	affected	_	_	VBD	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	activity	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	mitochondria	_	_	NN	_	_	_	_	_
29	enzymes	_	_	NNS	_	_	_	_	_
30	involved	_	_	VBN	_	_	_	_	_
31	in	_	_	IN	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	TCA	_	_	NN	_	_	_	_	_
34	cycle	_	_	NN	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	resulting	_	_	VBG	_	_	_	_	_
37	in	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	enhancement	_	_	NN	_	_	_	_	_
40	of	_	_	IN	_	_	_	_	_
41	energy	_	_	NN	_	_	_	_	_
42	metabolism	_	_	NN	_	_	_	_	_
43	in	_	_	IN	_	_	_	_	_
44	treated	_	_	VBN	_	_	_	_	_
45	mice	_	_	NNS	_	_	_	_	_
46	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	decreased	_	_	VBN	_	_	_	_	_
6	level	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	pyruvate	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	increased	_	_	VBN	_	_	_	_	_
11	levels	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	lactate	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	alanine	_	_	NN	_	_	_	_	_
16	were	_	_	VBD	_	_	_	_	_
17	highly	_	_	RB	_	_	_	_	_
18	related	_	_	VBN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	pyruvate	_	_	NN	_	_	_	_	_
21	metabolism	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Pyruvate	_	_	NNP	_	_	_	_	_
2	could	_	_	MD	_	_	_	_	_
3	be	_	_	VB	_	_	_	_	_
4	converted	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	acetyl-coenzyme	_	_	NN	_	_	_	_	_
7	A	_	_	NN	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	COA	_	_	NN	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	which	_	_	WDT	_	_	_	_	_
13	is	_	_	VBZ	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	vital	_	_	JJ	_	_	_	_	_
16	intermediate	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	synthesis	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	citrate	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Lactate	_	_	NN	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	alanine	_	_	NN	_	_	_	_	_
4	can	_	_	MD	_	_	_	_	_
5	also	_	_	RB	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	converted	_	_	VBN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	pyruvate	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	increased	_	_	VBN	_	_	_	_	_
5	lactate	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	alanine	_	_	NN	_	_	_	_	_
8	could	_	_	MD	_	_	_	_	_
9	promote	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	level	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	acetyl-COA	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	then	_	_	RB	_	_	_	_	_
16	up-regulate	_	_	VB	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	energy	_	_	NN	_	_	_	_	_
19	metabolism	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	sum	_	_	VB	_	_	_	_	_
3	up	_	_	RP	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	these	_	_	DT	_	_	_	_	_
6	results	_	_	NNS	_	_	_	_	_
7	indicated	_	_	VBD	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	enhancement	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	energy	_	_	NN	_	_	_	_	_
12	metabolism	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	mice	_	_	NNS	_	_	_	_	_
15	after	_	_	IN	_	_	_	_	_
16	rac	_	_	NN	_	_	_	_	_
17	-metalaxyl	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	metalaxyl-M	_	_	NN	_	_	_	_	_
20	exposure	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	perturbation	_	_	NN	_	_	_	_	_
5	degrees	_	_	NNS	_	_	_	_	_
6	induced	_	_	VBN	_	_	_	_	_
7	by	_	_	IN	_	_	_	_	_
8	metalaxy-M	_	_	NN	_	_	_	_	_
9	were	_	_	VBD	_	_	_	_	_
10	higher	_	_	JJR	_	_	_	_	_
11	than	_	_	IN	_	_	_	_	_
12	rac	_	_	NN	_	_	_	_	_
13	-metalaxy	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	energy	_	_	NN	_	_	_	_	_
16	metabolism	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	3.3	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Lipid	_	_	NN	_	_	_	_	_
2	Metabolism	_	_	NN	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	metalaxyl-M	_	_	NN	_	_	_	_	_
6	induced	_	_	VBD	_	_	_	_	_
7	two	_	_	CD	_	_	_	_	_
8	lipid	_	_	JJ	_	_	_	_	_
9	metabolism	_	_	NN	_	_	_	_	_
10	pathway	_	_	NN	_	_	_	_	_
11	fluctuations	_	_	NNS	_	_	_	_	_
12	including	_	_	VBG	_	_	_	_	_
13	glycerophospholipid	_	_	NN	_	_	_	_	_
14	metabolism	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	glyoxylate	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	dicarboxylate	_	_	NN	_	_	_	_	_
20	metabolism	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	no	_	_	DT	_	_	_	_	_
4	lipid	_	_	NN	_	_	_	_	_
5	metabolism	_	_	NN	_	_	_	_	_
6	pathway	_	_	NN	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	affected	_	_	VBN	_	_	_	_	_
9	by	_	_	IN	_	_	_	_	_
10	rac	_	_	NN	_	_	_	_	_
11	-metalaxyl	_	_	NN	_	_	_	_	_
12	exposure	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	According	_	_	VBG	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	metabolomics	_	_	NNS	_	_	_	_	_
4	data	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	metalaxyl-M	_	_	NNP	_	_	_	_	_
7	induced	_	_	VBD	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	increased	_	_	VBN	_	_	_	_	_
10	levels	_	_	NNS	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	choline	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	TMAO	_	_	NNP	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	decreased	_	_	VBN	_	_	_	_	_
17	levels	_	_	NNS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	PC	_	_	NNP	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	GPC	_	_	NNP	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Rac	_	_	NNP	_	_	_	_	_


1	-metalaxyl	_	_	NN	_	_	_	_	_
2	only	_	_	RB	_	_	_	_	_
3	induced	_	_	VBD	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	decreased	_	_	VBN	_	_	_	_	_
6	level	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	GPC	_	_	NNP	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	Such	_	_	JJ	_	_	_	_	_
2	metabolites	_	_	NNS	_	_	_	_	_
3	were	_	_	VBD	_	_	_	_	_
4	all	_	_	RB	_	_	_	_	_
5	related	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	lipid	_	_	JJ	_	_	_	_	_
8	metabolism	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	had	_	_	VBD	_	_	_	_	_
11	essential	_	_	JJ	_	_	_	_	_
12	effect	_	_	NN	_	_	_	_	_
13	on	_	_	IN	_	_	_	_	_
14	cholesterol	_	_	NN	_	_	_	_	_
15	level	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	digestive	_	_	JJ	_	_	_	_	_
18	system	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Choline	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	an	_	_	DT	_	_	_	_	_
4	important	_	_	JJ	_	_	_	_	_
5	nutrient	_	_	NN	_	_	_	_	_
6	that	_	_	WDT	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	required	_	_	VBN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	lipid	_	_	NN	_	_	_	_	_
11	transport	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	methyl-group	_	_	JJ	_	_	_	_	_
14	metabolism	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	neurotransmitter	_	_	NN	_	_	_	_	_
17	synthesis	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	cell	_	_	NN	_	_	_	_	_
20	membrane	_	_	NN	_	_	_	_	_
21	structure	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	signaling	_	_	VBG	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	choline	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	constituent	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	cell	_	_	NN	_	_	_	_	_
10	membranes	_	_	NNS	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	lipoprotein	_	_	NN	_	_	_	_	_
13	phospholipids	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	which	_	_	WDT	_	_	_	_	_
16	play	_	_	VBP	_	_	_	_	_
17	an	_	_	DT	_	_	_	_	_
18	important	_	_	JJ	_	_	_	_	_
19	role	_	_	NN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	integrity	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	cell	_	_	NN	_	_	_	_	_
25	membrane	_	_	NN	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	lipid	_	_	JJ	_	_	_	_	_
28	metabolism	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Increased	_	_	VBN	_	_	_	_	_
2	choline	_	_	NN	_	_	_	_	_
3	levels	_	_	NNS	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	urine	_	_	NN	_	_	_	_	_
6	samples	_	_	NNS	_	_	_	_	_
7	suggested	_	_	VBD	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	membrane	_	_	NN	_	_	_	_	_
10	fluidity	_	_	NN	_	_	_	_	_
11	was	_	_	VBD	_	_	_	_	_
12	disrupted	_	_	VBN	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	metalaxyl-M	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_
16	PC	_	_	NNP	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	GPC	_	_	NNP	_	_	_	_	_
19	are	_	_	VBP	_	_	_	_	_
20	known	_	_	VBN	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	be	_	_	VB	_	_	_	_	_
23	important	_	_	JJ	_	_	_	_	_
24	endogenous	_	_	JJ	_	_	_	_	_
25	metabolites	_	_	NNS	_	_	_	_	_
26	related	_	_	VBN	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	maintenance	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	choline	_	_	NN	_	_	_	_	_
31	homeostasis	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	bile	_	_	NN	_	_	_	_	_
34	acids	_	_	NNS	_	_	_	_	_
35	excretion	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	PC	_	_	NNP	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	GPC	_	_	NNP	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	not	_	_	RB	_	_	_	_	_
9	only	_	_	RB	_	_	_	_	_
10	essential	_	_	JJ	_	_	_	_	_
11	components	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	cell	_	_	NN	_	_	_	_	_
14	membranes	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	but	_	_	CC	_	_	_	_	_
17	also	_	_	RB	_	_	_	_	_
18	protect	_	_	VB	_	_	_	_	_
19	cell	_	_	NN	_	_	_	_	_
20	from	_	_	IN	_	_	_	_	_
21	oxidative	_	_	JJ	_	_	_	_	_
22	stress	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	lipotoxicity	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	decreased	_	_	VBN	_	_	_	_	_
3	levels	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	PC	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	GPC	_	_	NN	_	_	_	_	_
8	may	_	_	MD	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	good	_	_	JJ	_	_	_	_	_
11	indicators	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	oxidative	_	_	JJ	_	_	_	_	_
14	stress	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	lipotoxicity	_	_	NN	_	_	_	_	_
17	induced	_	_	VBN	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	metalaxyl-M	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_

